Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 27 Sep 2026 · Editorial standards

At a glance

Daiichi Sankyo is the lead sponsor of 63 current clinical trials in our USA, Japan, France, China, Spain, Italy, South Korea, Taiwan, Belgium, Germany, UK, Brazil, Australia, Canada, Netherlands, Poland, Portugal, Israel, Austria, Turkey, Czechia, Singapore, Switzerland, Ireland, Denmark, Mexico, Sweden, Norway, Egypt, India and EU (CTIS) registers. 31 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Trastuzumab deruxtecan, Datopotamab Deruxtecan and Pembrolizumab. The most-studied condition is Advanced Solid Tumor.

ClinicalTrials.gov trials by status

Recruiting3151%
Not yet open12%
Active, closed2948%

Trials by phase

Phase 31931%
Phase 11830%
Phase 2813%
Phase 1/2711%
Observational711%
Phase 2/323%

Clinical trials sponsored by Daiichi Sankyo

61 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
A Study of DS3610a in Participants With Advanced Solid Tumor NCT07159126 · Solid Tumors, Metastatic Solid Tumors	Phase 1	Recruiting	2025-10	USA, France, Japan
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer NCT06899126 · Non-small Cell Lung Cancer Drugs: Pembrolizumab, Pemetrexed, Trastuzumab deruxtecan	Phase 3	Recruiting	2025-10	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Portugal, Turkey, Brazil, Japan, South Korea, Taiwan
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer NCT07022483 · Endometrial Cancer Drug: Trastuzumab deruxtecan	Phase 3	Recruiting	2025-09	USA, China, Germany, France, Spain, Italy, Poland, Portugal, Japan, South Korea, Taiwan
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) NCT06362252 · Extensive Stage-small Cell Lung Cancer Drugs: Atezolizumab, Carboplatin, Ifinatamab Deruxtecan	Phase 1/2	Recruiting	2024-07	USA, France, Spain, Japan
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02) NCT06330064 · Recurrent or Metastatic Solid Tumors Drug: Ifinatamab Deruxtecan	Phase 1/2	Recruiting	2024-04	Ireland, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Portugal, Turkey, Brazil, Mexico, Japan, Taiwan, Australia
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer NCT05950945 · ClinicalTrials.gov ↗ · Breast Cancer Drug: Trastuzumab deruxtecan	Phase 3	Recruiting	2023-12	Ireland, USA, China, Spain, Italy, Netherlands, Belgium, Portugal, Brazil, Australia, Israel
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT06161025 · ClinicalTrials.gov ↗ · Solid Cancer Drugs: Paclitaxel, R-DXd, Topotecan	Phase 2/3	Recruiting	2024-02	UK, USA, China, Germany, France, Spain, Italy, Poland, Czechia, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors NCT05765851 · Advanced Solid Tumor Drug: Trastuzumab deruxtecan	Phase 1	Recruiting	2023-05	USA, France, Spain, Canada, Japan
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) NCT06174987 · Advanced Cancer, Metastatic Cancer Drug: Trastuzumab deruxtecan	Phase 3	Recruiting	2024-01	UK, USA, France, Spain, Italy, Belgium, Brazil, Japan, South Korea, Taiwan, Australia, Israel
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors NCT06644755 · Solid Tumors, Sarcoma	Phase 1	Recruiting	2024-11	USA, France, Netherlands, Belgium, South Korea
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) NCT07244341 · ClinicalTrials.gov ↗ · Metastatic Castration-resistant Prostate Cancer Drugs: Darolutamide, Valemetostat	Phase 1	Recruiting	2025-12	Ireland, USA, China, Japan
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) NCT06819007 · ClinicalTrials.gov ↗ · Ovarian Cancer Drugs: Bevacizumab, Trastuzumab deruxtecan	Phase 3	Recruiting	2025-03	UK, USA, India, China, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) NCT06644781 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Drugs: Docetaxel, Ifinatamab Deruxtecan, Irinotecan	Phase 3	Recruiting	2025-03	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Norway, Japan, South Korea, Taiwan
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors NCT06172478 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Melanoma, Head and Neck Cancer Drug: Patritumab deruxtecan	Phase 2	Recruiting	2024-02	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Norway, Canada, Japan, South Korea, Taiwan, Australia
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer NCT06203210 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Drugs: Amrubicin, Ifinatamab Deruxtecan, Lurbinectedin	Phase 3	Recruiting	2024-05	USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer NCT06731478 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Cancer Drugs: Keytruda, Pembrolizumab, Trastuzumab	Phase 3	Recruiting	2025-02	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma NCT07129993 · ClinicalTrials.gov ↗ · Urothelial Cancer, Bladder Cancer Drugs: Carboplatin, Cisplatin, Datopotamab Deruxtecan	Phase 2/3	Recruiting	2025-09	USA, China, Germany, France, Italy, Austria, Japan
A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia NCT07206472 · ClinicalTrials.gov ↗ · Primary Hypercholesterolaemia, Mixed Dyslipidemia	Observational	Recruiting	2026-03	Brazil
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors NCT05875168 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Metastatic Solid Tumor	Phase 1/2	Recruiting	2023-08	USA, China, France, Spain, Belgium, Canada, Japan, South Korea
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission NCT06824168 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Leukemia Drug: Quizartinib	Phase 2	Recruiting	2025-07	USA, China, Brazil, South Korea, Australia
First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors NCT07681882 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Metastatic Solid Tumor, Unresectable Solid Tumor	Phase 1	Recruiting	2026-08	Japan
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors NCT07015697 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Solid Tumors Drug: Trastuzumab deruxtecan	Phase 1	Recruiting	2025-07	USA, France, Spain, Brazil, Japan, South Korea, Taiwan
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China NCT06846996 · ClinicalTrials.gov ↗ · HER2-positive Gastric Cancer, HER2-positive Gastroesophageal Junction Drug: Trastuzumab deruxtecan	Observational	Recruiting	2025-02	China, Japan
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies NCT07220616 · ClinicalTrials.gov ↗ · Hematological Malignancies, B-cell Non-Hodgkin Lymphoma	Phase 1/2	Recruiting	2026-01	USA, France, Italy, Japan
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors NCT04145622 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Malignant Solid Tumor Drug: Ifinatamab Deruxtecan	Phase 1/2	Recruiting	2019-11	USA, Japan
A Study of DS5361b in Participants With Advanced Solid Tumors NCT07182591 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Drugs: Keytruda, Pembrolizumab	Phase 1	Recruiting	2025-10	USA, Japan
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer NCT07189403 · ClinicalTrials.gov ↗ · Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer	Phase 1	Recruiting	2025-11	UK, USA, France
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH) NCT06210776 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer Drug: Trastuzumab deruxtecan	Observational	Recruiting	2024-01	China, Japan
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN) NCT06809764 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Observational	Recruiting	2025-02	China
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment NCT04635111 · ClinicalTrials.gov ↗ · Hepatotoxicity, Tenosynovial Giant Cell Tumor	Observational	Recruiting	2021-01	USA
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment NCT06740799 · ClinicalTrials.gov ↗ · Hepatic Impairment Drug: Quizartinib	Phase 1	Recruiting	2024-09	USA
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events NCT07474649 · ClinicalTrials.gov ↗ · Coronary Atherosclerosis, Mixed Dyslipidemia, Hypercholesterolemia Drugs: Atorvastatin, Bempedoic acid, Ezetimibe	Phase 3	Not yet open	2026-09	Germany, Spain, Italy
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) NCT03401385 · Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer Drug: Datopotamab Deruxtecan	Phase 1	Active, closed	2018-01	USA, Japan
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) NCT04526691 · Advanced or Metastatic NSCLC Drugs: Carboplatin, Cisplatin, Datopotamab Deruxtecan	Phase 1	Active, closed	2020-09	USA, Spain, Italy, Japan, Taiwan
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] NCT03734029 · Breast Cancer Drugs: Capecitabine, Eribulin, Gemcitabine	Phase 3	Active, closed	2018-12	UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Switzerland, Austria, Portugal, Canada, Japan, South Korea, Taiwan, Israel, Egypt
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) NCT04704934 · Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Drugs: Paclitaxel, Ramucirumab, Trastuzumab deruxtecan	Phase 3	Active, closed	2021-05	Ireland, UK, China, Germany, France, Spain, Italy, Belgium, Poland, Portugal, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore, Israel
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) NCT04622319 · HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer Drugs: Trastuzumab deruxtecan, Trastuzumab emtansine	Phase 3	Active, closed	2020-12	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) NCT05280470 · Extensive-stage Small-cell Lung Cancer Drug: Ifinatamab Deruxtecan	Phase 2	Active, closed	2022-03	USA, China, Germany, France, Spain, Japan, South Korea, Taiwan
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy NCT05338970 · ClinicalTrials.gov ↗ · Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion Drug: Patritumab deruxtecan	Phase 3	Active, closed	2022-07	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Norway, Portugal, Canada, Japan, South Korea, Taiwan, Singapore, Australia
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) NCT04656652 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Datopotamab Deruxtecan, Docetaxel	Phase 3	Active, closed	2020-12	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Czechia, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer NCT04619004 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor Drug: Patritumab deruxtecan	Phase 2	Active, closed	2021-02	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Austria, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors NCT04707248 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma, Ovarian Tumor Drug: R-DXd	Phase 1	Active, closed	2020-12	USA, Japan
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations NCT05215340 · ClinicalTrials.gov ↗ · Metastatic Non Small Cell Lung Cancer Drugs: Datopotamab Deruxtecan, Keytruda, Pembrolizumab	Phase 3	Active, closed	2022-03	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML NCT06578247 · ClinicalTrials.gov ↗ · Leukemia Drug: Quizartinib	Phase 3	Active, closed	2024-11	UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Egypt
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) NCT05555732 · ClinicalTrials.gov ↗ · Metastatic Non Small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Datopotamab Deruxtecan	Phase 3	Active, closed	2023-01	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study) NCT06812117 · ClinicalTrials.gov ↗ · Diabetic Peripheral Neuropathic Pain	Observational	Active, closed	2025-01	China, Japan
A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT NCT04488822 · ClinicalTrials.gov ↗ · Tenosynovial Giant Cell Tumor	Phase 3	Active, closed	2020-09	China, Taiwan
DS-3201b in Participants With Lymphomas NCT02732275 · ClinicalTrials.gov ↗ · Lymphoma, Malignant, Non-hodgkin Lymphoma Drug: Valemetostat Tosylate	Phase 1	Active, closed	2016-03	USA, Japan
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors NCT04419532 · ClinicalTrials.gov ↗ · Solid Tumor, Advanced Cancer, Metastatic Solid Tumor	Phase 1	Active, closed	2020-10	USA, Canada, Japan
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] NCT03529110 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Trastuzumab deruxtecan, Trastuzumab emtansine	Phase 3	Active, closed	2018-08	UK, USA, China, Germany, France, Spain, Italy, Belgium, Canada, Brazil, Japan, South Korea, Taiwan, Australia
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer NCT03260491 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer (NSCLC) Drug: Patritumab deruxtecan	Phase 1	Active, closed	2017-10	USA, Spain, Netherlands, Japan, South Korea, Taiwan
Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer NCT07092254 · Triple Negative Breast Cancer	Observational	Active, closed	2025-09	USA
Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy NCT04433234 · ClinicalTrials.gov ↗ · Duchenne Muscular Dystrophy	Phase 2	Active, closed	2020-06	Japan
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer NCT04042701 · ClinicalTrials.gov ↗ · Breast Cancer, Non-small Cell Lung Carcinoma Drugs: Keytruda, Pembrolizumab, Trastuzumab deruxtecan	Phase 1	Active, closed	2020-02	UK, USA, France, Spain
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) NCT06660654 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Metastatic Solid Tumors Drug: R-DXd	Phase 2	Active, closed	2025-01	USA, China, France, Spain, Italy, Belgium, Denmark, Japan, South Korea
A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma NCT04458272 · ClinicalTrials.gov ↗ · WHO Grade II Glioma Drug: Safusidenib	Phase 2	Active, closed	2020-07	Japan
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) NCT04703192 · ClinicalTrials.gov ↗ · Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma Drug: Valemetostat Tosylate	Phase 2	Active, closed	2021-06	UK, USA, Germany, France, Spain, Italy, Netherlands, Canada, Japan, South Korea, Taiwan, Australia
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations NCT06644768 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Lung Cancer Drugs: Pembrolizumab, Valemetostat Tosylate	Phase 1/2	Active, closed	2024-10	USA, China, Brazil, Japan
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors NCT06244485 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Drugs: Datopotamab Deruxtecan, Trastuzumab deruxtecan, Valemetostat Tosylate	Phase 1	Active, closed	2024-02	USA, China, Italy, Japan
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood NCT03793478 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia Drugs: Cytarabine, Etoposide, Fludarabine	Phase 1/2	Active, closed	2018-08	USA, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Canada, Israel
HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer NCT04676477 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer (NSCLC) Drugs: Osimertinib, Patritumab deruxtecan	Phase 1	Active, closed	2021-06	USA, Japan, South Korea, Taiwan

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Daiichi Sankyo in the EU trials register (CTIS)

2 trials

Authorised or ongoing trials in the EU Clinical Trials Information System with Daiichi Sankyo as sponsor. Some are the same study as a ClinicalTrials.gov record above; the two registries share no common ID. Trials with a site in Ireland are listed first.

Study	Phase	Status	Countries
A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC targeting CD37, for Hematological Malignancies. 2025-522595-87-00 · CTIS ↗ · Neoplasms Drugs: Epcoritamab, Rituximab	Phase 1	Ongoing	France, Italy
A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed During or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment. TROPION-Urothelial03 (TU03). 2024-516906-47-00 · CTIS ↗ · Neoplasms Drugs: Carboplatin, Cisplatin, Datopotamab Deruxtecan	Phase 3	Ongoing	Netherlands, Germany, Norway + 8 more

Drugs in Daiichi Sankyo trials

40 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Daiichi Sankyo trials

68 conditions

Advanced Solid Tumor8 Breast Cancer5 Non-small Cell Lung Cancer5 Advanced Cancer3 Metastatic Solid Tumor3Recurrent or Metastatic Solid Tumors2Metastatic Castration-resistant Prostate Cancer2 Gastric Cancer2 Metastatic Non Small Cell Lung Cancer2 Leukemia2 Triple Negative Breast Cancer2 Solid Tumors2 Metastatic Solid Tumors2Tenosynovial Giant Cell Tumor2Acute Myeloid Leukemia2 Non-Small Cell Lung Cancer (NSCLC)2Mixed Dyslipidemia2Gastric Cancer, Adenocarcinoma1Gastroesophageal Junction Adenocarcinoma1HER2-Positive Primary Breast Cancer1Residual Invasive Breast Cancer1Metastatic Cancer1Solid Cancer1Nonsquamous Non-small Cell Lung Cancer1

By trial register

Register	Trials	Recruiting
Clinical trials in USA	50	26
Clinical trials in Japan	48	23
Clinical trials in France	34	19
Clinical trials in China	33	17
Clinical trials in Spain	33	15
Clinical trials in Italy	29	13
Clinical trials in South Korea	28	13
Clinical trials in Taiwan	27	11
Clinical trials in Belgium	23	11
Clinical trials in Germany	22	9
Clinical trials in UK	20	8
Clinical trials in Brazil	19	11
Clinical trials in Australia	18	9
Clinical trials in Canada	17	6
Clinical trials in Netherlands	16	7
Clinical trials in Poland	15	8
Clinical trials in Portugal	14	7
Clinical trials in Israel	10	3
Clinical trials in Austria	10	4
Clinical trials in Turkey	9	5
Clinical trials in Czechia	8	4
Clinical trials in Singapore	7	1
Clinical trials in Switzerland	7	1
Clinical trials in Ireland	5	3
Clinical trials in Denmark	5	2
Clinical trials in Mexico	5	1
Clinical trials in Sweden	5	2
Clinical trials in Norway	5	3
Clinical trials in Egypt	2	0
Clinical trials in India	2	2
EU register (CTIS)	2	—

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Advanced Solid Tumor

Sponsor	Trials
BeOne Medicines	12
TORL Biotherapeutics	5
OncoC4	5
LaNova Medicines	5
MediLink Therapeutics (Suzhou)	4
Suzhou Zelgen Biopharmaceuticals	4
BioNTech	3
EMD Serono Research & Development Institute	3
GI Innovation	3
Hansoh BioMedical R&D Company	3

Sponsors with the most current trials registered for this condition.

Questions about Daiichi Sankyo trials

How many clinical trials does Daiichi Sankyo sponsor?

Daiichi Sankyo is the lead sponsor of 61 current trials on ClinicalTrials.gov in our USA, Japan, France, China, Spain, Italy, South Korea, Taiwan, Belgium, Germany, UK, Brazil, Australia, Canada, Netherlands, Poland, Portugal, Israel, Austria, Turkey, Czechia, Singapore, Switzerland, Ireland, Denmark, Mexico, Sweden, Norway, Egypt and India registers, and 2 authorised or ongoing trials in the EU register (CTIS), as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are Daiichi Sankyo trials recruiting?

Yes. 31 of its 61 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Daiichi Sankyo testing?

Its current trials name 40 drugs and biologicals as interventions. The most frequent are Trastuzumab deruxtecan (16), Datopotamab Deruxtecan (8), Pembrolizumab (7), Ifinatamab Deruxtecan (6) and Keytruda (6). The number in brackets is how many of its trials name each drug.

Does Daiichi Sankyo have clinical trials in Ireland?

Yes. 5 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Daiichi Sankyo clinical trials